Teriparatide BS Mochida
Teriparatide biosimilar developed by Mochida Pharmaceutical. Reference product Forsteo (Forteo in the United States).
Brands by market: Teriparatide BS MOCHIDA (Japan) · Commercial partner or holder: Mochida Pharmaceutical
FDAnot listed
EMAnot listed
PMDASep 2019approved
HCnot listed
CDSCOnot listed
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
PMDA
Japan · Teriparatide BS MOCHIDA
Pharmaceuticals and Medical Devices Agency and MHLWApprovedBrand
Teriparatide BS MOCHIDA
Holder or applicant
Mochida Pharmaceutical
Pathway
Biosimilar (MHLW approval on PMDA review)
Approved
Sep 2019
Indications as licensed
Osteoporosis at high risk of fracture
Presentations
600 microgram subcutaneous kit
Note
Teriparatide Biosimilar 1, the first in Japan.
Source
S020
HC
Canada
Not listed by HC.
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- PMDASep 2019Approved by MHLW
Sources
S020PMDA, list of approved biosimilar products in Japan (as of July 2026) Primary (regulator)
Planning teriparatide biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.